Les points sur les i Dr Claire SKENTELBERY – Secretary General, European Biotechnology Foundation Prof. J. BALTHAZART and Dr Julie BAKKER, ULg-GIGA Neurosciences Isabelle RAUSIN, ULg-Interface and Jérôme EECKHOUT, ULg-ARD Health researchers : double your funding opportunities and those of your U.S. partners, by targeting jointly E.C. and N.I.H. projects
33
Embed
Biotech Santé | E.C. and N.I.H. projects : double your funding opportunities by Claire Skentelbery | Liege Creative, 15.02.12
A joint organization of LIEGE CREATIVE, Interface Entreprises-Université Liège and GIGA, based on shared experiences and available support in order to help researchers accessing these funding opportunities.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Les points sur les i
Dr Claire SKENTELBERY – Secretary General, European Biotechnology Foundation Prof. J. BALTHAZART and Dr Julie BAKKER, ULg-GIGA Neurosciences Isabelle RAUSIN, ULg-Interface and Jérôme EECKHOUT, ULg-ARD
Health researchers : double your funding opportunities and those of your U.S. partners, by targeting jointly E.C. and N.I.H. projects
Avec le soutien de :
15.2.2012 www.european-biotechnology.net 1
Building transatlantic research partnerships Claire Skentelbery European Biotechnology Network
Mission for today
• Introduce European Biotechnology Network • Understand tools available to build US
research partnerships • Suitability for your work • Plan 2012 opportunities • Get to work!
15.2.2012 www.european-biotechnology.net 2
Getting introduced
• Cross sectoral network in biotech • Mission to facilitate partnership • Delivering biotechnology – critical mass,
accelerated pace • Biotechnology Funding Hub • Strong focus on SME/industry inclusion • Global focus for Europe
15.2.2012 www.european-biotechnology.net 3
Liege as a Network member • For researchers and support staff • Sign up to the Network each and every one! • Free subscription to European Biotechnology
News – sign up to get your personal copy • Funding Hub news – get the latest updates • Free access to Network events/training • Priority speaker places at events • Direct assistance in project development • Hub around which we can build projects
15.2.2012 www.european-biotechnology.net 4
Offer today • Doing the business in the US!
– March 29th, Brussels – Small intensive workshop – Logistics of building a successful US partnership – €100 Corporate members
• Building Transatlantic partnerships – March 30th, Brussels – NIH, EC, DoD, Gates Foundation – Broader look at funding and experiences – 2 free places for Corporate members
15.2.2012 www.european-biotechnology.net 5
Biotechnology Funding Hub
• Track funding open to SMEs in Europe; EC, Eurostars, eurotransbio, NIH, DoD
• Mission to build collaborative partnerships • Work with members to find projects and
DoD 2012 – in a nutshell • Secret funding tool – wide funding range • Projects, fellowships – open to global application • Few active in Europe, almost all in UK • Significant opportunities for partnered applications:
– Across all biology – Diagnostics, vaccines, disease management, real
time & remote technologies – Projects in Europe include breast cancer,
immunotherapy, lung cancer etc. 8 topics currently open
– Last call in 2012 – Lots of support in Liege – Opportunity to engage US partners for EC
projects - € directly from Brussels – Strong SME partnership opportunity – EBN working with NIH to matchmake
research for FP7
15.2.2012 www.european-biotechnology.net 9
NIH: Where to start? • NIH enormous research and funding platform • Aim of talk to address from practical perspective
– What is it? – Opportunities for me – How to access projects – Chances of success – Best approach – Finding partners – Who can help me?
15.2.2012 www.european-biotechnology.net 10
What is NIH? • NIH’s mission is to seek fundamental knowledge about
the nature and behaviour of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.
• Broad programme – basic-applied/clinical research • $31.2 billion annual budget – squeezed in 2011/12
15.2.2012 www.european-biotechnology.net 11
Institutes of the NIH
• 27! • Cancer, eye, Heart lung and blood, human genome,
ageing, alcohol abuse, allergy & infectious disease, arthritis & skin disease, imaging and bioengineering, child health, deafness & communication disorders, dental & craniofacial, diabetes, digestive & kidney diseases, drug abuse, env health, general medical sciences, mental health, neurological disorders & stroke, nursing, rare/neglected diseases
• New - National Center for Advancing Translational Sciences’
15.2.2012 www.european-biotechnology.net 12
Each Institute has…
• Own mission and structure • Own research funding programme and budget • Dedicated funding or joint funding with other
Institutes • Budget varies hugely
15.2.2012 www.european-biotechnology.net 13
Opportunities open for me?
• Focus on main funding programmes suitable • Programmes launched – open 4 years • 3 deadlines/year – multiple application
opportunities • Main programmes open to non-US application For non-US success, must either:
– Be not available in US – Significant benefit to US research
15.2.2012 www.european-biotechnology.net 14
Programme announcements (PA) • General areas of high priority • Proposals submitted at any time of year • Evaluated 3 times/year • Evaluation timescale:
services, indirect costs, travel – No max cost BUT:
• €25,000 modules up to module limit of $250k • Max 5 periods – usually 12 months each • All non-US applicants must have detailed budget
– 1 resubmission allowed – Encouraged to contact NIH
15.2.2012 www.european-biotechnology.net 18
Project types - P01
• Research program projects • Broad based • Multidisciplinary • Long term • All address different elements of common
objectives • Industry encouraged – non-US also • No budget max unless stated
15.2.2012 www.european-biotechnology.net 19
Funding level/success rates? Varies between Institute: 2010 examples • NCI: 17% - $516 million • NIAID (allergy/infectious disease): 24% - $506 million • NHLBI (heart/lung/blood): 20% - $416 million • NIGMS (general): 27% - $336 million • NIDDK (diabetes/digestive/kidney): 26% - $333 million This counts project renewal: higher % for those New project: More like 10% success
15.2.2012 www.european-biotechnology.net 20
Proposal contents
• Pleasingly similar between all! • Get familiar with PHS398 – core example
15.2.2012 www.european-biotechnology.net 21
Proposal core elements – Budget for initial/whole – Research plan:
• Aims • Strategy – see next slide • Inclusion – women/minorities • Enrolment • Agent research • Leadership plan • Consortium/contractual plan
• First time European applicant? • Find suitable call topic • Find European organisations already playing in
US – several in the room! • Find US partners you KNOW and are active in
NIH • Understand history of funding in this area • Try and join/develop US-led proposal • Go prepared to a key US conf and partner
15.2.2012 www.european-biotechnology.net 29
Resources to use
• Searchable database on NIH website http://projectreporter.nih.gov/reporter.cfm • Many funding reports available • Find groups active in your field – great starting